NANOMEDIC INC
Salt Lake City, UT · Biotech · Private
Iron chelating drugs targeting bone loss in sickle cell disease patients
- Grants
- $2.5M
- 10 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2015201620172018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · New therapeutics targeting skeletal excessive Fe for thalassemia major bone loss | $229,998 | |
| Federal grant | Department of Health and Human Services · Phase I · New therapeutics targeting skeletal excessive Fe for thalassemia major bone loss | $229,998 | |
| Federal grant | Department of Health and Human Services · Phase I · A method for early and easy detection of Alzheimer's disease | $198,278 | |
| Federal grant | Department of Health and Human Services · Phase I · A method for early and easy detection of Alzheimer s disease | $540,125 | |
| Federal grant | Department of Health and Human Services · Phase I · A method for early and easy detection of Alzheimer's disease | $198,278 | |
| Federal grant | Department of Health and Human Services · Phase I · A method for early and easy detection of Alzheimer's disease | $143,569 | |
| Federal grant | Department of Health and Human Services · Phase I · A therapeutic approach for potential prevention of aromatase inhibitor-induced bone loss | $222,976 | |
| Federal grant | Department of Health and Human Services · Phase I · A therapeutic approach for potential prevention of aromatase inhibitor-induced bone loss | $222,976 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing novel therapeutic approaches for osteopenia and osteoporosis in patients with sickle cell disease | $248,486 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing novel therapeutic approaches for osteopenia and osteoporosis in patients with sickle cell disease | $248,486 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1159 | NEUTHERAPEUTICS, LLC | — | — |
| 1160 | IMAGO PHARMACEUTICALS, INC. | — | — |
| 1161 | Trove Labs Inc | — | — |
| 1162 | NANOMEDIC INC | — | — |
| 1163 | AnkyrBio LLC | — | — |
| 1164 | YOURCHOICE THERAPEUTICS INC | — | — |
| 1165 | ABALONE BIO, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.